Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics.

[1]  J. McMurry,et al.  Immunogenicity Screening Using in Silico Methods: Correlation between T‐Cell Epitope Content and Clinical Immunogenicity of Monoclonal Antibodies , 2009 .

[2]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[3]  Qing Zhang,et al.  Immune epitope database analysis resource (IEDB-AR) , 2008, Nucleic Acids Res..

[4]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[5]  Anne S De Groot,et al.  Immunogenicity of protein therapeutics. , 2007, Trends in immunology.

[6]  E. Celis,et al.  Immunogenicity of protein therapeutics and the interplay between tolerance and antibody responses. , 2007, Drug discovery today.

[7]  D. Masterman,et al.  Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion , 2007, Journal of Clinical Immunology.

[8]  T. Boone,et al.  Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. , 2007, Clinical immunology.

[9]  Leonard Moise,et al.  Prediction of immunogenicity for therapeutic proteins: state of the art. , 2007, Current opinion in drug discovery & development.

[10]  Julie A McMurry,et al.  Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. , 2007, Vaccine.

[11]  Devan V Mehrotra,et al.  A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects. , 2006, AIDS research and human retroviruses.

[12]  M. Sayegh,et al.  A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. , 2006, Journal of the American Society of Nephrology : JASN.

[13]  P. S. Andersen,et al.  Reduced Susceptibility of Recombinant Polyclonal Antibodies to Inhibitory Anti-Variable Domain Antibody Responses , 2006, The Journal of Immunology.

[14]  J. Reveille.  The genetic basis of autoantibody production. , 2006, Autoimmunity reviews.

[15]  A. D. De Groot,et al.  Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease. , 2006, The Journal of clinical endocrinology and metabolism.

[16]  J. McMurry,et al.  Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island , 2006, Human vaccines.

[17]  K. Moudgil,et al.  The Unveiling of Hidden T‐Cell Determinants of a Native Antigen by Defined Mediators of Inflammation: Implications for the Pathogenesis of Autoimmunity , 2006, Scandinavian journal of immunology.

[18]  William W. Kwok,et al.  Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide , 2006, The Journal of experimental medicine.

[19]  Anne S De Groot,et al.  Immunomics: discovering new targets for vaccines and therapeutics. , 2006, Drug discovery today.

[20]  Francisco A. Chaves,et al.  The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. , 2005, Immunity.

[21]  Vladimir Brusic,et al.  Computational methods for prediction of T-cell epitopes--a framework for modelling, testing, and applications. , 2004, Methods.

[22]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[23]  William N. Rom,et al.  HLA-A2-Restricted CD8+-Cytotoxic-T-Cell Responses to Novel Epitopes in Mycobacterium tuberculosis Superoxide Dismutase, Alanine Dehydrogenase, and Glutamine Synthetase , 2004, Infection and Immunity.

[24]  Jeffrey A. Bluestone,et al.  Opinion-regulatory lymphocytes: Natural versus adaptive regulatory T cells , 2003, Nature Reviews Immunology.

[25]  A. Haselbeck.  Epoetins: differences and their relevance to immunogenicity , 2003, Current medical research and opinion.

[26]  Julie McMurry,et al.  Immuno‐informatics: Mining genomes for vaccine components , 2002, Immunology and cell biology.

[27]  J. Berzofsky,et al.  High-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection. , 2001, The Journal of clinical investigation.

[28]  R. Kiessling,et al.  DNA immunization of HLA transgenic mice with a plasmid expressing mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T cell responses that can be augmented by cytokines. , 2001, Human gene therapy.

[29]  C Crimi,et al.  Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.

[30]  J. Altman,et al.  An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. , 2001, AIDS research and human retroviruses.

[31]  G Y Ishioka,et al.  Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. , 1999, Journal of immunology.

[32]  D. Weber,et al.  Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules. , 1999, Journal of immunology.

[33]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[34]  A. D. De Groot,et al.  An interactive Web site providing major histocompatibility ligand predictions: application to HIV research. , 1997, AIDS research and human retroviruses.

[35]  J. Lieberman,et al.  Prediction of HIV peptide epitopes by a novel algorithm. , 1996, AIDS research and human retroviruses.

[36]  V. Engelhard,et al.  Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. , 1995, International immunology.

[37]  J. Berzofsky,et al.  CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. , 1995, Journal of immunology.

[38]  L. Wysocki,et al.  T cell recognition of somatically-generated Ab diversity. , 1994, Journal of immunology.

[39]  J. Vielmetter,et al.  Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. , 2006, Clinical immunology.

[40]  E. Carter,et al.  Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. , 2005, Tuberculosis.

[41]  B. Diamond.  Speculations on the immunogenicity of self proteins. , 2003, Developments in biologicals.

[42]  M. Wadhwa,et al.  Immunogenicity of GM-CSF products in cancer patients following immunostimulatory therapy with GM-CSF. , 2003, Developments in biologicals.

[43]  H. Häcker,et al.  Signal transduction pathways activated by CpG-DNA. , 2000, Current topics in microbiology and immunology.